An update on the pharmacological treatment of obsessive-compulsive disorder

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 5, 2007, Pages 563-583

  Fontenelle, Leonardo F ^a   Nascimento, Antonio L ^a   Mendlowicz, Mauro V ^b   Shavitt, Roseli G ^c   Versiani, Marcio ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Obsessive compulsive disorder; Serotonin re uptake inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LORAZEPAM; MEMANTINE; MIRTAZAPINE; MORPHINE; NICOTINE GUM; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PINDOLOL; PLACEBO; QUETIAPINE; REBOXETINE; RISPERIDONE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; NEUROLEPTIC AGENT;

ALGORITHM; BLOOD PRESSURE; BLURRED VISION; CAPSULOTOMY; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONSTIPATION; DEPRESSION; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FATIGUE; GILLES DE LA TOURETTE SYNDROME; HUMAN; LOW DRUG DOSE; MEDICAL RECORD REVIEW; MEDLINE; META ANALYSIS; MONOTHERAPY; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PALLIDOTOMY; PANIC; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; THALAMOTOMY; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA; CONTROLLED CLINICAL TRIAL; EVIDENCE BASED MEDICINE; EXPERT WITNESS; RANDOMIZED CONTROLLED TRIAL;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; COGNITIVE THERAPY; EVIDENCE-BASED MEDICINE; EXPERT TESTIMONY; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS;

EID: 34047200959     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.5.563     Document Type: Review

References (211)

1. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision. American Psychiatric Press, Washington, DC (2000).
2. FONTENELLE FL, MEDLOWICZ MV, VERSIANI M: The descriptive epidemiology of obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) 30(3):327-337.
3. DE GRAAF R, BIJL RV, RAVELLI A, SMIT F, VOLLEBERGH WA: Predictors of first incidence of DSM-III-R psychiatric disorders in the general population: findings from the Netherlands Mental Health Survey and Incidence Study. Acta Psychiatr. Scand. (2002) 106(4):303-313.
4. MAYEROVITCH JI, DU FORT GG, KAKUMA R, BAND RC, NEWMAN SC, PINARD G: Treatment seeking for obsessive-compulsive disorder: role of obsessive-compulsive disorder symptoms and comorbid psychiatric diagnoses. Compr. Psychiatry (2003) 44(2):162-168.
5. FINEBERG NA, GALE TM: Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int. J. Neuropsychopharmacol. (2005) 8:107-129
6. SOOMRO GM: Obsessive compulsive disorder. Clin. Evid. (2002) 8:991-1002
7. BLANCO C, OLFSON M, STEIN DJ, SIMPSOM HB, GAMEROFF MJ, NARROW WH: Treatment of obsessive-compulsive disorder by US psychiatrists. J. Clin. Psychiatry (2006) 67(6):946-951
8. EISEN JL, RASMUSSEN SA, PHILLIPS KA et al.: Insight and treatment outcome in obsessive-compulsive disorder. Compr. Psychiatry (2001) 42:494-497.
9. KORAN LM, LEVENTHAL JL, FIREMAN B, JACOBSON A: Pharmacotherapy of obsessive-compulsive disorder in a health maintenance organization. Am. J. Health Syst. Pharm. (2000) 57:1972-1978
10. DENYS D, VAN MEGEN H, WESTENBERG H: The adequacy of pharmacotherapy in out-patients with obsessive-compulsive disorder. Int. Clin. Psychopharmacol. (2002) 17:109-114.
11. PALLANTI S, QUERCIOLI L: Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog. Neuropsychopharmacol Biol. Psychiatry (2006) 30:400-412.
12. COX BJ, SWINSON RP, MORRISON B, LEE PS: Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis. J. Behav. Ther. Exp. Psychiatry (1993) 24:149-153.
13. PICCINELLI M, PINI S, BELLANTUONO C, WILKINSON G: Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br. J. Psychiatry (1995) 166:424-443.
14. STEIN DJ, SPADACCINI E, HOLLANDER E: Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int. Clin. Psychopharmacol. (1995) 10:11-18.
15. ABRAMOWITZ JS: Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J. Consult. Clin. Psychol. (1997) 65:44-52.
16. ACKERMAN DL, GREENLAND S: Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J. Clin. Psychopharmacol. (2002) 22:309-317.
17. EDDY KT, DUTRA L, BRADLEY R, WESTEN D: A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin. Psychol. Rev. (2004) 24:1011-1013.
18. BLOCH MH, LANDEROS-WEISENBERGER A, KELMENDI B, CORIC V, BRACKEN MB, LECKMAN JF: A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol. Psychiatry (2006) 11:622-632.
19. SKAPINAKIS P, PAPATHEODOROU T, MAVREAS V: Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur. Neuropsychopharmacol. (2007) 17:79-93.
20. FINEBERG NA, STEIN DJ, PREMKUMAR P et al.: Adjunctive quetiapine for serotonin re-uptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int. Clin. Psychopharmacol. (2006) 21:337-343.
21. KAPLAN A, HOLLANDER E: A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr. Serv. (2003) 54:1111-1118.
22. WALSH KH, MCDOUGLE CJ: Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder. Expert Opin. Pharmacother. (2004) 5:2059-2067.
23. SCHRUERS K, KONING K, LUERMANS J, HAACK MJ, GRIEZ E: Obsessive-compulsive disorder: a critical review of therapeutic perspectives. Acta Psychiatr. Scand. (2005) 111:261-271.
24. DENYS D: Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr. Clin. North Am. (2006) 29:553-584.
25. CANADIAN PSYCHIATRIC ASSOCIATION: Clinical practice guidelines. Management of anxiety disorders. Can. J. Psychiatry (2006) 51(8 Suppl. 2):9S-91S.
26. BALDWIN DS, ANDERSON IM, NUTT DJ et al.: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. (2005) 19:567-596.
27. GREIST JH, BANDELOW B, HOLLANDER E et al.: WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr. (2003) 8:7-16.
28. BANDELOW B, ZOHAR J, HOLLANDER E et al.: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders. World J. Biol. Psychiatry (2002) 3:171-199.
29. THE EXPERT CONSENSUS PANEL FOR OBSESSIVE-COMPULSIVE DISORDER: Treatment of obsessive-compulsive disorder. J. Clin. Psychiatry (1997) 58(Suppl. 4):2-72.
30. PERSE TL, GREIST JH, JEFFERSON JW, ROSENFELD R, DAR R: Fluvoxamine treatment of obsessive-compulsive disorder. Am. J. Psychiatry (1987) 144:1543-1548.
31. GOODMAN WK, PRICE LH, RASMUSSEN SA, DELGADO PL, HENINGER GR, CHARNEY DS: Efficacy of fluvoxamine in obsessive-compulsive disorder, a double-blind comparison with placebo. Arch. Gen. Psychiatry (1989) 46:36-44.
32. JENIKE MA, HYMAN S, BAER L et al.: A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am. J. Psychiatry (1990) 147:1209-1215.
33. HOLLANDER E, KORAN LM, GOODMAN WK et al.: A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J. Clin. Psychiatry (2003) 64:640-647.
34. MONTGOMERY SA, MCINTYRE A, OSTERHEIDER M et al.: A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur. Neuropsychopharmacol. (1993) 3:143-152.
35. TOLLEFSON GD, BIRKETT M, KORAN L, GENDUSO L: Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J. Clin. Psychiatry (1994) 55(Suppl.):69-78.
36. CHOUINARD G, GOODMAN W, GREIST J et al.: Results of a double-blind placebo-controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol. Bull. (1990) 26:279-284.
37. GREIST JH, JEFFERSON JW, KOBAK KA et al.: A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int. Clin. Psychopharmacol. (1995) 10:57-65.
38. JENIKE MA, BAER L, SUMERGRAD P, MINICHIELLLLO WE, HOLLAND A, SEYMOUR R: Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo. Am. J. Psychiatry (1990) 147:923-928.
39. ZOHAR J, JUDGE R: Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br. J. Psychiatry (1996) 169:468-474.
40. HOLLANDER E, ALLEN A, STEINER M, WHEADON DE, OAKES R, BURNHAM DB: Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J. Clin. Psychiatry (2003) 64:1113-1121.
41. KAMIJIMA K, MURASAKI M, ASAI M et al.: Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients. Psychiatry Clin. Neurosci. (2004) 58:427-433.
42. MONTGOMERY SA, KASPER S, STEIN DJ, BANG HEDEGAARD K, LEMMING OM: Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int. Clin. Psychopharmacol. (2001) 16:75-86.
43. STEIN DJ, TONNIOR B, ANDERSEN EW: Escitalopram in the treatment of OCD. 159th Annual Meeting of the American Psychiatric Association. Toronto, Canada (2006). Abstr. 299.
44. PALLANTI S, QUERCIOLI L, BRUSCOLI M: Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J. Clin. Psychiatry (2004) 65:1394-1399.
45. CROCKETT BA, CHURCHILL E, DAVIDSON JR: A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. Ann. Clin. Psychiatry (2004) 16:127-132.
46. FONTENELLE LF, MENDLOWICZ MV, KALAF J, DOMINGUES AM, VERSIANI M: Obsessions with aggressive content emerging during the course of panic disorder: a different subtype of obsessive-compulsive disorder? Int. Clin. Psychopharmacol. (2005) 20:343-346.
47. NOORBALA AA, HOSSEINI SH, MOHAMMADI MR, AKHONDZADEH S: Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial. J. Clin Pharm. Ther (1998) 23:155-159.
48. YARYURA-TOBIAS JA, NEZIROGLU FA: Venlafaxine in obsessive-compulsive disorder. Arch. Gen. Psychiatry (1996) 53:653-654.
49. FERNANDEZ-CORDOBA E, LOPEZ-IBOR ALIÑO J: La monoclomipramina en enfermos psiquiatricos resistentes a otros tratamientos. Acta Luso-Esp Neurol Psiquiatr Cienc Afines (1967) 26:119-147.
50. DELL'OSSO B, NESTADT G, ALLEN A, HOLLANDER E: Serotonin-noradrenaline re-uptake inhibitors in the treatment of obsessive-compulsive disorder: a critical review. J. Clin. Psychiatry (2006) 67:600-610.
51. MAJ J, STALA L, GORKA Z, ADAMUS A: Comparison of the pharmacological actions of desmethylclomipramine and clomipramine. Psychopharmacology (1982) 78:165-169.
52. AUSTIN LS, LYDIARD RB, BALLENGER JC et al.: Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. Biol. Psychiatry (1991) 30:225-232.
53. FALLON BA, LIEBOWITZ MR, CAMPEAS R et al.:Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch. Gen. Psychiatry (1998) 55:918-924.
54. KORAN LM, PALLANTI S, PAIVA RS, QUERCIOLI L: Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder. Eur. Neuropsychopharmacol. (1998) 8:121-126.
55. KORAN LM, SALLEE FR, PALLANTI S: Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am. J. Psychiatry (1997) 154:396-401.
56. KORAN LM, ABOUJAOUDE E, WARD H et al.: Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder. J. Clin. Psychopharmacol. (2006) 26:79-83
57. METIN O, YAZICI K, TOT S, YAZICI AE: Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum. Psychopharmacol. (2003) 18:463-467.
58. BROWNE M, HORN E, JONES TT: The benefits of clomipramine-fluoxetine combination in obsessive compulsive disorder. Can. J. Psychiatry (1993) 38:242-243.
59. RASMUSSEN SA: Lithium and tryptophan augmentation in clomipramine-resistant obsessive-compulsive disorder. Am. J. Psychiatry (1984) 141:1283-1285.
60. STERN L, ZOHAR J, COHEN R, SASSON Y: Treatment of severe, drug-resistant obsessive compulsive disorder with the 5ht1d agonist sumatriptan. Eur. Europsychopharmacol. (1998) 8:325-328.
61. JUDD FK, CHUA P, LYNCH C, NORMAN T: Fenfluramine augmentation of clomipramine treatment of obsessive compulsive disorder. Aust. NZ. J. Psychiatry (1991) 25:412-414.
62. MATSUNAGA H, MATSUI T, OHYA K et al.: A benzisothiazole derivative and antipsychotic agent, perospirone, for augmentation of selective serotonin re-uptake inhibitors (SSRIs) in refractory obsessive-compulsive disorder (OCD): two patient case series. Int. J. Psychiatry Clin. Prac. (2006) 10:1145
63. FONTENELLE LF, MENDLOWICZ MV, MIGUEL EC, VERSIANI M: Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder. World J. Biol. Psychiatry (2005) 6:57-59.
64. CORIC V, MILANOVIC S, WASYLINK S, PATEL P, MALISON R, KRYSTAL JH: Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (2003) 167:219-220.
65. CORIC V, TASKIRAN S, PITTENGER C et al.: Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol. Psychiatry (2005) 58:424-428.
66. PASQUINI M, BIONDI M: Memantine augmentation for refractory obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) 30:1173-1175.
67. POYUROVSKY M, WEIZMAN R, WEIZMAN A, KORAN L: Memantine for treatment-resistant OCD. Am. J. Psychiatry (2005) 162:2191-2192.
68. KUMAR TC, KHANNA S: Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust. NZ J. Psychiatry (2000) 34:527-528.
69. HOLLANDER E, DELL'OSSO B: Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder. Int. Clin. Psychopharmacol. (2006) 21:189-191.
70. RUBIO G, JIMENEZ-ARRIERO MA, MARTINEZ-GRAS I, MANZANARES J, PALOMO T: The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder. J. Clin. Psychopharmacol. (2006) 26:341-344.
71. DELTITO JA: Valproate pretreatment for the difficult-to-treat patient with OCD. J. Clin. Psychiatry (1994) 55:500.
72. LUNDBERG S, CARLSSON A, NORFELDT P, CARLSSON ML: Nicotine treatment of obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry (2004) 28:1195-1199.
73. PASQUINI M, GARAVINI A, BIONDI M: Nicotine augmentation for refractory obsessive-compulsive disorder. A case report. Prog. Neuropsychopharmacol. Biol. Psychiatry (2005) 29:157-159.
74. IWATA Y, KOTANI Y, HOSHINO R, TAKEI N, IYO M, MORI N: Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder. J. Clin. Psychiatry (2000) 61:528-529.
75. BAIRD P: The interactive metabolism effect of oxcarbazepine coadministered with tricyclic antidepressant therapy for OCD symptoms. J. Clin. Psychopharmacol. (2003) 23:419-420.
76. MCMEEKIN H: Successful treatment of obsessive compulsive disorder with oxcarbazepine. A case report. J S C Med. Assoc (2002) 98:316-320.
77. HOLLANDER E, FRIEDBERG J, WASSERMAN S, ALLEN A, BIRNBAUM M, KORAN LM: Venlafaxine in treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry (2003) 64:546-550.
78. MARAZZITI D: Venlafaxine treatment of obsessive-compulsive disorder: case reports. CNS Spectr (2003) 8:421-422.
79. DELL'OSSO B, ALTAMURA AC, ALLEN A, HOLLANDER E: Brain stimulation techniques in the treatment of obsessive-compulsive disorder: current and future directions. CNS Spectr. (2005) 10:966-979.
80. MALETZKY B, MCFARLAND B, BURT A: Refractory obsessive compulsive disorder and ECT. Convuls. Ther. (1994) 10:34-42.
81. LOO CK, SCHWEITZER I, PRATT C: Recent advances in optimizing electroconvulsive therapy. Aust. NZ J. Psychiatry (2006) 40:632-638.
82. GRUBER RP: ECT for obsessive-compulsive symptoms. (Possible mechanisms of action). Dis. Nerv. Syst. (1971) 32:180-182.
83. KHANNA S, GANGADHAR BN, SINHAV, RAJENDRA PN, CHANNABASAVANNA SM: Electroconvulsive therapy in obsessive-compulsive disorder. Convuls. Ther. (1988) 4:314-320.
84. SOYKA M, NIEDERECKER M, MEYENDORF R: [Successful treatment of a therapy-refractory compulsive syndrome by electroconvulsive therapy]. Nervenarzt (1991) 62:448-450.
85. HUSAIN MM, LEWIS SF, THORNTON WL: Maintenance ECT for refractory obsessive-compulsive disorder. Am. J. Psychiatry (1993) 150:1899-1900.
86. WOHLFAHRT A: [Electroconvulsive therapy in compulsive syndromes. A case report]. Nervenarzt (1996) 67:397-399.
87. CHAVES MP, CRIPPA JA, MORAIS SL, ZUARDI AW: Electroconvulsive therapy for coexistent schizophrenia and obsessive-compulsive disorder. J. Clin. Psychiatry (2005) 66:542-543.
88. GREENBERG BD, GEORGE MS, MARTIN JD et al.: Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study. Am. J. Psychiatry (1997) 154:867-869.
89. ALONSO P, PUJOL J, CARDONER N et al.: Right prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Am. J. Psychiatry (2001) 158:1143-1145.
90. SACHDEV PS, MCBRIDE R, LOO CK, MITCHELL PB, MALHI GS, CROKER VM: Right versus left prefrontal transcranial magnetic stimulation for obsessive-compulsive disorder: a preliminary investigation. J. Clin. Psychiatry (2001) 62:981-984.
91. MANTOVANI A, LISANBY SH, PIERACCINI F, ULIVELLI M, CASTROGIOVANNI P, ROSSI S: Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS). Int. J. Neuropsychopharmacol. (2006) 9:95-100.
92. PRASKO J, PASKOVA B, ZALESKY R et al.: The effect of repetitive transcranial magnetic stimulation (rTMS) on symptoms in obsessive compulsive disorder. A randomized, double-blind, sham controlled study. Neuro. Endocrinol. Lett. (2006) 27:327-332.
93. MARTIN JL, BARBANOJ MJ, PEREZ V, SACRISTAN M: Transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder. Cochrane Database Syst. Rev. (2003) 3:CD003387
94. WICHMANN T, DELONG MR: Deep brain stimulation for neurologic and neuropsychiatric disorders. Neuron (2006) 52:197-204.
95. ANDERSON WS, LENZ FA: Surgery insight: deep brain stimulation for movement disorders. Nat. Clin. Pract. Neurol. (2006) 2:310-320.
96. GROSS RE: Deep brain stimulation in the treatment of neurological and psychiatric disease. Expert Rev. Neurother. (2004) 4:465-478.
97. NUTTIN B, COSYNS P, DEMEULEMEESTER H, GYBELS J, MEYERSON B: Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder. Lancet (1999) 354:1526.
98. NUTTIN BJ, GABRIELS L, VAN KUYCK K, COSYNS P: Electrical stimulation of the anterior limbs of the internal capsules in patients with severe obsessive-compulsive disorder: anecdotal reports. Neurosurg. Clin. N. Am. (2003) 14:267-274.
99. GABRIELS L, COSYNS P, NUTTIN B, DEMEULEMEESTER H, GYBELS J: Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: psychopathological and neuropsychological outcome in three cases. Acta Psychiatry Scand. (2003) 107:275-282.
100. ANDERSON KE, MULLINS JL: Behavioural changes associated with deep brain stimulation surgery for Parkinson's disease. Curr. Neurol. Neurosci. Rep. (2003) 3:306-313.
101. AOUIZERATE B, CUNY E, MARTIN-GUEHL C et al.: Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression. Case report. J. Neurosurg. (2004) 101:682-686.
102. ABELSON JL, CURTIS GC, SAGHER O et al.: Deep brain stimulation for refractory obsessive-compulsive disorder. Biol. Psychiatry (2005) 57:510-516.
103. RAUCH SL, DOUGHERTY DD, MALONE D et al.: A functional neuroimaging investigation of deep brain stimulation in patients with obsessive-compulsive disorder. J. Neurosurg. (2006) 104:558-565.
104. GREENBERG BD, MALONE DA, FRIEHS GM et al.: Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology (2006) 31:2394.
105. OKUN MS, MANN G, FOOTE KD et al.: Internal capsule and nucleus accumbens region DBS: Responses observed during active and sham programming. J. Neurol. Neurosurg. Psychiatry (In Press).
106. MATHEW SJ, YUDOFSKY SC, MCCULLOUGH LB, TEASDALE TA, JANKOVIC J: Attitudes toward neurosurgical procedures for Parkinson's disease and obsessive-compulsive disorder. J. Neuropsychiatry Clin. Neurosci. (1999) 11:259-267.
107. LOPES AC, DE MATHIS ME, CANTERAS MM, SALVAJOLI JV, DEL PORTO JA, MIGUEL EC: [Update on neurosurgical treatment for obsessive compulsive disorder]. Rev. Bras. Psiquiatr. (2004) 26:62-66.
108. GREENBERG BD, MURPHY DL, RASMUSSEN SA: Neuroanatomically based approaches to obsessive-compulsive disorder. Neurosurgery and transcranial magnetic stimulation. Psychiatr. Clin. North Am. (2000) 23(3):671-686, xii.
109. FODSTAD H, STRANDMAN E, KARLSSON B, WEST KA: Treatment of chronic obsessive compulsive states with stereotactic anterior capsulotomy or cingulotomy. Acta Neurochir. (1982) 62:1-23.
110. MINDUS P, RASMUSSEN SA, LINDQUIST C: Neurosurgical treatment for refractory obsessive-compulsive disorder: implications for understanding frontal lobe function. J. Neuropsychiatry Clin. Neurosci. (1994) 6:467-477.
111. JENIKE MA, BAER L, BALLANTINE T et al.: Cingulotomy for refractory obsessive-compulsive disorder. A long-term follow-up of 33 patients. Arch. Gen. Psychiatry (1991) 48:548-555.
112. RAUCH SL, DOUGHERTY DD, COSGROVE GR et al.: Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for obsessive compulsive disorder. Biol. Psychiatry (2001) 50:659-667.
113. RAUCH SL, KIM H, MAKRIS N et al.: Volume reduction in the caudate nucleus following stereotactic placement of lesions in the anterior cingulate cortex in humans: a morphometric magnetic resonance imaging study. J. Neurosurg. (2000) 93:1019-1025.
114. SIMPSON HB, GORFINKLE KS, LIEBOWITZ MR: Cognitive-behavioural therapy as an adjunct to serotonin re-uptake inhibitors in obsessive-compulsive disorder: an open trial. J. Clin. Psychiatry (1999) 60:584-590.
115. KAMPMAN M, KEIJSERS GP, HOOGDUIN CA, VERBRAAK MJ: Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine. Acta Psychiatr. Scand. (2002) 106:314-319.
116. TOLIN DF, MALTBY N, DIEFENBACH GJ, HANNAN SE, WORHUNSKY P: Cognitive-behavioural therapy for medication nonresponders with obsessive-compulsive disorder: a wait-list-controlled open trial. J. Clin. Psychiatry (2004) 65:922-931.
117. ANDERSON SW, BOOKER MB JR: Cognitive behavioural therapy versus psychosurgery for refractory obsessive-compulsive disorder. J. Neuropsychiatry Clin. Neurosci. (2006) 18:129.
118. HOLLANDER E, BIENSTOCK CA, KORAN LM et al.: Refractory obsessive-compulsive disorder: state-of-the-art treatment. J. Clin. Psychiatry (2002) 63(Suppl. 6):20-29.
119. PIGOTT TA, PATO MT, BERNSTEIN SE et al.: Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioural and biological results. Arch. Gen. Psychiatry (1990) 47:926-932.
120. DENYS D, VAN MEGEN HJ, VAN DER WEE N, WESTENBERG HG: A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J. Clin. Psychiatry (2004) 65:37-43.
121. FONTENELLE LF, DE MENEZES GB, VERSIANI M: [Patients with obsessive-compulsive disorder may only respond to the fifth drug trial]. 19th Brazilian Congress of Psychiatry Recife. Brazil (2001).
122. PITTENGER C, KRYSTAL JH, CORIC V: Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx (2006) 3:69-81.
123. ZOHAR J, KENNEDY JL, HOLLANDER E, KORAN LM: Serotonin-1D hypothesis of obsessive-compulsive disorder: an update. J. Clin. Psychiatry (2004) 65(Suppl. 14):18-21.
124. GOODMAN WK, KOZAK MJ, LIEBOWITZ M, WHITE KL: Treatment of obsessive-compulsive disorder with fluvoxamine: a multi-centre, double-blind, placebo-controlled trial. Int. Clin. Psychopharmacol. (1996) 11:21-29.
125. GOODMAN WK, PRICE LH, DELGADO PL et al.: Specificity of serotonin re-uptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch. Gen. Psychiatry (1990) 47:577-585.
126. SMERALDI E, ERZEGOVESI S, BIANCHI I, PASQUALI L, COCCHI S, RONCHI P: Fluvoxamine versus clomipramine treatment in obsessive-compulsive disorder: a preliminary study. N. Trends Exp. Clin. Psychiatry (1992) 8:63-65.
127. FREEMAN CP, TRIMBLE MR, DEAKIN JF, STOKES TM, ASHFORD JJ: Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J. Clin. Psychiatry (1994) 55:301-305.
128. KORAN LM, MCELROY SL, DAVIDSON JR, RASMUSSEN SA, HOLLANDER E, JENIKE MA: Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J. Clin. Psychopharmacol. (1996) 16:121-129.
129. MILANFRANCHI A, RAVAGLI S, LENSI P, MARAZZITI D, CASSANO GB: A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int. Clin. Psychopharmacol. (1997) 12:131-136.
130. ROUILLON F: A double-blind comparison of fluvoxamine and clomipramine in OCD. European Neuropsychopharmacology (1998) 8(Suppl.):260-261.
131. LOPEZ-IBOR JJ JR, SAIZ J, COTTRAUX J et al.: Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur. Neuropsychopharmacol. (1996) 6:111-118.
132. KRONIG MH, APTER J, ASNIS G et al.: Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J. Clin. Psychopharmacol. (1999) 19:172-176.
133. BISSERBE JC, LANE RM, FLAMENT MF et al.: A double-blind comparison of sertraline and clomipramine in out-patients with obsessive-compulsive disorder. Eur. Psychiatry (1997) 12:82-93
134. DENYS D, VAN DER WEE N, VAN MEGEN HJ, WESTENBERG HG: A double-blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J. Clin. Psychopharmacol. (2003) 23:568-575.
135. PRASAD A: A double-blind study of imipramine versus zimelidine in treatment of obsessive compulsive neurosis. Pharmacopsychiatry (1984) 17:61-62.
136. ALBERT U, AGUGLIA E, MAINA G, BOGETTO F: Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J. Clin. Psychiatry (2002) 63:1004-1009.
137. RAVIZZA L, ALBERT U, CEREGATO A: Venlafaxine in OCD. Presented at the International Obsessive-Compulsive Disorder Conference. Sardinia, Italy (2001).
138. YARYURA-TOBIAS JA, NEZIROGLU F: The action of chlorimipramine in obsessive-compulsive neurosis: a pilot study. Curr. Ther. Res. Clin. Exp. (1975) 17:111-116.
139. MONTGOMERY SA, MONTGOMERY DB, FINEBERG N: Early response with clomipramine in obsessive-compulsive disorder-a placebo-controlled study. Prog. Neuropsychopharmacol Biol. Psychiatry (1990) 14:719-727.
140. THOREN P, ASBERG M, CRONHOLM B, JORNESTEDT L, TRASKMAN L: Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch. Gen. Psychiatry (1980) 37:1281-1285
141. MAVISSAKALIAN M, TURNER SM, MICHELSON L, JACOB R: Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? II. Am. J. Psychiatry (1985) 142:572-576.
142. JENIKE MA, BAER L, SUMMERGRAD P, WEILBURG JB, HOLLAND A, SEYMOUR R: Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients. Am. J. Psychiatry (1989) 146:1328-1330.
143. MAVISSAKALIAN MR, JONES B, OLSON S, PEREL JM: Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels. J. Clin. Psychopharmacol. (1990) 10:261-268.
144. KATZ RJ, LANDAU P, DEVEAUGH-GEISS J, HAKKARAINEN H: Therapeutic effects of anafranil in obsessive compulsive disorder. Recent clinical findings. Prog. Clin. Biol. Res. (1990) 361:489-493.
145. GREIST JH, JEFFERSON JW, ROSENFELD R, GUTZMANN LD, MARCH JS, BARKLAGE NE: Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients. J. Clin. Psychiatry (1990) 51:292-297.
146. DEVEAUGH-GEISS J, MOROZ G, BIEDERMAN J et al.: Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder-a multicenter trial. J. Am. Acad. Child. Adolesc. Psychiatry (1992) 31:45-49.
147. Clomipramine in the treatment of patients with obsessive-compulsive disorder. the clomipramine collaborative study group. Arch. Gen. Psychiatry (1991) 48:730-738.
148. PIDRMAN V, TUMA I: Citalopram versus clomipramine in double-blind therapy of obsessive-compulsive disorder. Abstracts 11th Congress European College of Neuropsychopharmacology. Paris, France (1998).
149. VULINK NC, DENYS D, WESTENBERG HG: Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study. J. Clin. Psychiatry (2005) 66:228-230.
150. VALLEJO J, OLIVARES J, MARCOS T, BULBENA A, MENCHON JM: Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial. Br. J. Psychiatry (1992) 161:665-670.
151. JENIKE MA, BAER L, MINICHIELLO WE, RAUCH SL, BUTTOLPH ML: Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am. J. Psychiatry (1997) 154:1261-1264.
152. INSEL TR, MURPHY DL, COHEN RM, ALTERMAN I, KILTS C, LINNOILA M: Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgiline. Arch. Gen. Psychiatry (1983) 40:605-612.
153. JENIKE MA: Rapid response of severe obsessive-compulsive disorder to tranylcypromine. Am. J. Psychiatry (1981) 138:1249-1250.
154. JENIKE MA, SURMAN OS, CASSEM NH, ZUSKY P, ANDERSON WH: Monoamine oxidase inhibitors in obsessive-compulsive disorder. J. Clin. Psychiatry (1983) 44:131-132.
155. ANANTH J, PECKNOLD JC, VAN DEN STEEN N, ENGELSMANN F: Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog. Neuropsychopharmacol. (1981) 5:257-262.
156. VOLAVKA J, NEZIROGLU F, YARYURA-TOBIAS JA: Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatry Res. (1985) 14:85-93.
157. ZOHAR J, INSEL TR: Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol. Psychiatry (1987) 22:667-687.
158. HOEHN-SARIC R, NINAN P, BLACK DW et al.: Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch. Gen. Psychiatry (2000) 57:76-82.
159. NOORBALA AA, HOSSEINI SH, MOHAMMADI MR, AKHONDZADEH S: Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial. J. Clin. Pharm. Ther. (1998) 23:155-159.
160. PIGOTT TA, L'HEUREUX F, RUBENSTEIN CS, BERNSTEIN SE, HILL JL, MURPHY DL: A double-blind, placebo-controlled study of trazodone in patients with obsessive-compulsive disorder. J. Clin. Psychopharmacol. (1992) 12:156-162.
161. HEWLETT WA, SCHMID SP, SALOMON RM: Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J. Clin. Psychiatry (2003) 64:1025-1030.
162. PATO MT, PIGOTT TA, HILL JL, GROVER GN, BERNSTEIN S, MURPHY DL: Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am. J. Psychiatry (1991) 148:127-129.
163. FUX M, LEVINE J, AVIV A, BELMAKER RH: Inositol treatment of obsessive-compulsive disorder. Am. J. Psychiatry (1996) 153:1219-1221.
164. HEWLETT WA, VINOGRADOV S, AGRAS WS: Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J. Clin. Psychopharmacol. (1992) 12:420-430.
165. CROCKETT BA, CHURCHILL E, DAVIDSON JR: A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. Ann. Clin. Psychiatry (2004) 16:127-132.
166. HOLLANDER E, KAPLAN A, STAHL SM: A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J. Biol. Psychiatry (2003) 4:30-34.
167. STEIN DJ, HOLLANDER E, MULLEN LS et al.: Comparison of clomipramine, alprazolam, and placebo in the treatment of obsessive-compulsive disorder. Human Psychopharmacology (1992) 7:389-395.
168. KOBAK KA, TAYLOR LV, BYSTRITSKY A et al.: St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int. Clin. Psychopharmacol. (2005) 20:299-304.
169. GEISLER A, SCHOU M: [Lithium for obsessive-compulsive neuroses. A double-blind therapeutic trial]. Nord Psykiatr Tidsskr (1969) 23:493-555.
170. HESSO R, THORELL LH: [Lithium treatment for obsessive-compulsive neuroses. A little clinical-therapeutic pilot study of the double-blind crossover type]. Nord Psykiatr Tidsskr (1969) 23:496-469.
171. KHANNA S: Carbamezapine in obsessive-compulsive disorder. Clin. Neuropharmacol. (1988) 11:478-481.
172. JOFFE RT, SWINSON RP: Carbamazepine in obsessive-compulsive disorder. Biol. Psychiatry (1987) 22:1169-1171.
173. JENIKE MA, BROTMAN AW: The EEG in obsessive-compulsive disorder. J. Clin. Psychiatry (1984) 45:122-124.
174. CONNOR KM, PAYNE VM, GADDE KM, ZHANG W, DAVIDSON JR: The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J. Clin. Psychiatry (2005) 66:49-51.
175. ALTEMUS M, GREENBERG BD, KEULER D, JACOBSON KR, MURPHY DL: Open trial of flutamide for treatment of obsessive-compulsive disorder. J. Clin. Psychiatry (1999) 60:442-445.
176. EPPERSON CN, MCDOUGLE CJ, PRICE LH: Intranasal oxytocin in obsessive-compulsive disorder. Biol. Psychiatry (1996) 40:547-549.
177. MCDOUGLE CJ, GOODMAN WK, LECKMAN JF, LEE NC, HENINGER GR, PRICE LH: Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch. Gen. Psychiatry (1994) 51:302-308.
178. MCDOUGLE CJ, EPPERSON CN, PELTON CH, WASYLINK S, PRICE LH: A double-blind, placebo-controlled study of risperidone addition in serotonin re-uptake inhibitor-refractory obsessive-compulsive disorder. Arch. Gen. Psychiatry (2000) 57:794-801.
179. HOLLANDER E, BALDINI ROSSI N, SOOD E, PALLANTI S: Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol. (2003) 6:397-401.
180. ERZEGOVESI S, GUGLIELMO E, SILIPRANDI F, BELLODI L: Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur. Neuropsychopharmacol. (2005) 15:69-74.
181. BYSTRITSKY A, ACKERMAN DL, ROSEN RM et al.: Augmentation of serotonin re-uptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J. Clin. Psychiatry (2004) 65:565-568.
182. SHAPIRA NA, WARD HE, MANDOKI M et al.: A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol. Psychiatry (2004) 55:553-555.
183. ATMACA M, KULOGLU M, TEZCAN E, GECICI O: Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int. Clin. Psychopharmacol. (2002) 17:115-119.
184. DENYS D, DE GEUS F, VAN MEGEN HJ, WESTENBERG HG: A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin re-uptake inhibitors. J. Clin. Psychiatry (2004) 65:1040-1048.
185. CAREY PD, VYTHILINGUM B, SEEDAT S, MULLER JE, VAN AMERINGEN M, STEIN DJ: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry (2005) 5:5.
186. FINEBERG NA, SIVAKUMARAN T, ROBERTS A, GALE T: Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int. Clin. Psychopharmacol. (2005) 20:223-226.
187. METIN O, YAZICI K, TOT S, YAZICI AE: Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum. Psychopharmacol. (2003) 18:463-467.
188. PALLANTI S, QUERCIOLI L, PAIVA RS, KORAN LM: Citalopram for treatment-resistant obsessive-compulsive disorder. Eur. Psychiatry (1999) 14:101-106.
189. PALLANTI S, QUERCIOLI L, KORAN LM: Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J. Clin. Psychiatry (2002) 63:796-801.
190. PATHAK S, COTTINGHAM EM, MCCONVILLE BJ: The use of sumatriptan in the treatment of obsessive-compulsive disorder in an adolescent. J. Child Adolesc. Psychopharmacol. (2003) 13(Suppl. 1):S93-S94.
191. HOLLANDER E, COHEN LJ, DECARIA C et al.: Timing of neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels in OCD. Biol. Psychiatry (1993) 34:407-413.
192. HOLLANDER E, DECARIA CM, SCHNEIER FR, SCHNEIER HA, LIEBOWITZ MR, KLEIN DF: Fenfluramine augmentation of serotonin re-uptake blockade antiobsessional treatment. J. Clin. Psychiatry (1990) 51:119-123.
193. DANNON PN, SASSON Y, HIRSCHMANN S, IANCU I, GRUNHAUS LJ, ZOHAR J: Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo-controlled trial. Eur. Neuropsychopharmacol. (2000) 10:165-169.
194. MUNDO E, GUGLIELMO E, BELLODI L: Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int. Clin. Psychopharmacol. (1998) 13:219-224.
195. PIGOTT TA, L'HEUREUX F, HILL JL, BIHARI K, BERNSTEIN SE, MURPHY DL: A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J. Clin. Psychopharmacol. (1992) 12:11-18.
196. GRADY TA, PIGOTT TA, L'HEUREUX F, HILL JL, BERNSTEIN SE, MURPHY DL: Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am. J. Psychiatry (1993) 150:819-821.
197. MCDOUGLE CJ, GOODMAN WK, LECKMAN JF et al.: Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am. J. Psychiatry (1993) 150:647-649.
198. NINAN PT, KORAN LM, KIEV A et al.: High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J. Clin. Psychiatry (2006) 67:15-22.
199. BARR LC, GOODMAN WK, ANAND A, MCDOUGLE CJ, PRICE LH: Addition of desipramine to serotonin re-uptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am. J. Psychiatry (1997) 154:1293-1295.
200. VAN AMERINGEN M, MANCINI C, PATTERSON B, BENNETT M: Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress. Anxiety (2006) 23:1-5.
201. CORA-LOCATELLI G, GREENBERG BD, MARTIN JD, MURPHY DL: Valproate monotherapy in an SRI-intolerant OCD patient. J. Clin. Psychiatry (1998) 59:82.
202. KORAN LM, ABOUJAOUDE E, BULLOCK KD, FRANZ B, GAMEL N, ELLIOTT M: Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry (2005) 66:353-359.
203. PIGOTT TA, PATO MT, L'HEUREUX F et al.: A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J. Clin. Psychopharmacol. (1991) 11:242-248.
204. MCDOUGLE CJ, PRICE LH, GOODMAN WK, CHARNEY DS, HENINGER GR: A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J. Clin. Psychopharmacol. (1991) 11:175-184.
205. SEEDAT S, STEIN DJ: Inositol augmentation of serotonin re-uptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial. Int. Clin. Psychopharmacol. (1999) 14:353-356.
206. FUX M, BENJAMIN J, NEMETS B: A placebo-controlled crossover trial of adjunctive EPA in OCD. J. Psychiatr. Res. (2004) 38:323-325.
207. PIGOTT TA, PATO MT, L'HEUREUX F et al.: A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J. Clin. Psychopharmacol. (1991) 11:242-248.
208. DE MATHIS MA, DINIZ JB, DO ROSARIO MC et al.: What is the optimal way to subdivide obsessive-compulsive disorder? CNS Spectr. (2006) 11:762-768.
209. EL MANSARI M, BLIER P: Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) 30:362-373.
210. DICKERSIN K: The existence of publication bias and risk factors for its occurrence. JAMA (1990) 263:1385-1389.
211. GILBODY SM, SONG F, EASTWOOD AJ, SUTTON A: The causes, consequences and detection of publication bias in psychiatry. Acta Psychiatr. Scand. (2000) 102:241-249.